Trial ALS drug shows potential to drag out patient endurance Kumar Jeetendra | October 18, 2020 An experimental medicine that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the capacity to also prolong patient survival. The findings come from a clinical trial conducted by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts …
Free radicals might be significant for the brain to stay versatile Kumar Jeetendra | December 6, 2020 Reactive oxygen molecules, also known as”free radicals”, are generally considered dangerous. Researchers from the German Center for Neurodegenerative Diseases (DZNE) and the Center for Regenerative Therapies Dresden (CRTD) at TU Dresden published the findings in the journal Cell Stem Cell. The researchers focused on the”hippocampus”, a brain region that is regarded as the control center …
Analysts recognize interface among ALS and collection of DNA-RNA hybrids in the genome Kumar Jeetendra | January 13, 2021 Researchers from the University of Seville and the University of Pavia have identified a connection between Amyotrophic Lateral Sclerosis (ALS) and the accumulation of DNA-RNA hybrids in the genome. The accumulation of these hybrids causes increased genomic damage and boosts genetic instability. This finding will make it possible to better understand the molecular basis of …
Small molecule drug can weaken the triggers of neuroinflammation, preclinical review shows Kumar Jeetendra | September 24, 2021 Neuroinflammation may cause worse outcomes in cases of stroke, injuries to the brain or injury, and can increase the severity of neurodegenerative diseases such as ALS, Parkinson’s, or Alzheimer’s. This suggests that reducing neuroinflammation might be an exciting new method to treat neurological disorders and neuropathic pain caused by neuroinflammation. In a preclinical study , …
